Cannabis UseNCT03987347
Health Condition of Cannabis Consumers in the Canadian Population
An observational study of Cannabis Use and Old Age, run by Jewish General Hospital at 1 site in Canada.
Trial summary
This study evaluates the health condition and its evolution with time of Cannabis consumers in the Canadian population. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Cannabis Use, Old Age, Health Risk
- What is being tested?
- Observational
- How many people
- 0 participants
- Where
- 1 siteCanada
- Study dates
- 1 Dec 2020to 1 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: People from Canada who were enrolled in the Canadian Longitudinal Study on Aging the last 20 years, and who have consumed different cannabis products for different reasons either recreational or medical.
Who may be able to join
- Living in Canada the last 20 years
- Being 60 years and over
- Being consumer of cannabis
Who cannot join
- Living outside Canada the last 20 years
- Have never consumed cannabis
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Health Condition of Cannabis Consumers in the Canadian Population: A Population-based Observational Cohort Study
This study evaluates the health condition and its evolution with time of Cannabis consumers in the Canadian population.
Read the detailed description
In Canada, legalization of recreational use is likely to have decreased the perception of risks associated with Cannabis use, and means that the reported adverse effects of Cannabis are not so important, suggesting that Cannabis may be useful for their illness as an alternative or complementary therapeutic.
More Canadian physicians prescribed Cannabis for their patients. Both Recreational and medical use of Cannabis increase and will continue to grow up in the next coming years. Regardless, the typology of Cannabis use, more information on the health condition of Cannabis consumers may be helpful for the medical prescription of Cannabis, in particular in older adults who are more at risk of side effects.
- Conditions
- Cannabis Use, Old Age, Health Risk
- Being tested
- Observational
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationalOther
People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
What is being measured
The primary outcome is the main question the study is designed to answer.
Neurocognitive disorder
The decrease of cognitive function changes the activities of daily living to older adults. Instrumental Activities of Daily Living Scale ( IADLs) will be used to assess independent living skills to people who are a diagnosis of mild cognitive impairment. A summary score range from 0 ( low function, dependent) to 8 ( high function, independent) will be given to each participant based on their daily activities.
Measured: around 20 years
Secondary outcomes (1)
Depression
It will be used the Centre for Epidemiologic Studies-Depression Scale (CES-D) that rates how often over the past week people experience symptoms that are associated with depression. In scoring the Center for Epidemiologic Studies Depression Scale, a value of 0,1,2,3 is assigned to a response based on the emotional feelings that the participants have.
Measured: around 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2019
- Study start1 Dec 2020
- Primary completion1 Dec 2020
- Study completion1 Dec 2020
Why it stopped: No authorization from CLSA database scientific committee
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cannabis UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jewish General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Olivier Beauchet, Jewish General Hospital
- Investigators
- Olivier Beauchet, MD, Principal investigator, Jewish General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03987347
- Sponsor's protocol ID
- 2020-1830
- Status last verified
- Dec 2020
- First submitted
- 13 Jun 2019
- Last updated
- 17 Dec 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Health Condition of Cannabis Consumers in the Canadian Population: A Population-based Observational Cohort Study
- ClinicalTrials.gov ID
- NCT03987347
- Acronym / sponsor ID
- 2020-1830
- Conditions
- Cannabis Use, Old Age, Health Risk
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: No authorization from CLSA database scientific committee
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Jewish General HospitalUniversity, hospital or other
- Study start
- 1 Dec 2020 (actual)
- Primary completion
- 1 Dec 2020 (actual)
- Study completion
- 1 Dec 2020 (actual)
- First posted
- 17 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the health condition and its evolution with time of Cannabis consumers in the Canadian population.
Detailed description
In Canada, legalization of recreational use is likely to have decreased the perception of risks associated with Cannabis use, and means that the reported adverse effects of Cannabis are not so important, suggesting that Cannabis may be useful for their illness as an alternative or complementary therapeutic.
More Canadian physicians prescribed Cannabis for their patients. Both Recreational and medical use of Cannabis increase and will continue to grow up in the next coming years. Regardless, the typology of Cannabis use, more information on the health condition of Cannabis consumers may be helpful for the medical prescription of Cannabis, in particular in older adults who are more at risk of side effects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- People from Canada who were enrolled in the Canadian Longitudinal Study on Aging the last 20 years, and who have consumed different cannabis products for different reasons either recreational or medical.
Key inclusion criteria (3 listed)
- Living in Canada the last 20 years
- Being 60 years and over
- Being consumer of cannabis
Key exclusion criteria (2 listed)
- Living outside Canada the last 20 years
- Have never consumed cannabis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationalPeople who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire. | Other | – |
Primary outcome
Neurocognitive disorder
Time frame: around 20 years
The decrease of cognitive function changes the activities of daily living to older adults. Instrumental Activities of Daily Living Scale ( IADLs) will be used to assess independent living skills to people who are a diagnosis of mild cognitive impairment. A summary score range from 0 ( low function, dependent) to 8 ( high function, independent) will be given to each participant based on their daily activities.
1 secondary outcome
Depression
Time frame: around 20 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2020.
Related trials for Cannabis Use
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Olivier Beauchet, MD principal investigator
Jewish General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cannabis Use and Old Age, run by Jewish General Hospital at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 17 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neurocognitive disorder (time frame: around 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2020.